CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($) $ in Millions	6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024
Cash Flows from Operating Activities
Net income	$ 9,514	$ 10,228
Adjustments to reconcile net income to net cash provided by operating activities:
Amortization	1,198	1,087
Depreciation	1,020	1,029
Income from investments in equity securities, net	(189)	(200)
Charge for research and development asset acquisition	0	656
Deferred income taxes	(634)	(232)
Share-based compensation	411	379
Other	444	174
Net changes in assets and liabilities	(5,971)	(4,394)
Net Cash Provided by Operating Activities	5,793	8,727
Cash Flows from Investing Activities
Capital expenditures	(2,092)	(1,652)
Purchases of securities and other investments	(1,207)	(64)
Proceeds from sales of securities and other investments	1,057	320
Acquisition of Harpoon Therapeutics, Inc., net of cash acquired	0	(746)
Other	(15)	(303)
Net Cash Used in Investing Activities	(2,257)	(2,445)
Cash Flows from Financing Activities
Net change in short-term borrowings	48	0
Proceeds from issuance of debt	0	3,600
Payments on debt	(2,500)	(751)
Dividends paid to stockholders	(4,127)	(3,936)
Purchases of treasury stock	(2,509)	(373)
Proceeds from exercise of stock options	31	160
Other	(254)	(298)
Net Cash Used in Financing Activities	(9,311)	(1,598)
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash	530	(220)
Net (Decrease) Increase in Cash, Cash Equivalents and Restricted Cash	(5,245)	4,464
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of $76 and $68 at January 1, 2025 and 2024, respectively, included in Other current assets)	13,318	6,909
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $66 and $69 at June 30, 2025 and 2024, respectively, included in Other current assets)	$ 8,073	$ 11,373